计算溶液所需的质量、体积或浓度。
为什么选择此级别
提供 ≥99% 纯度，适用于对基线干扰要求严格的色谱和分析工作流程。
储存与运输
-20°C储存。超低温运输 。请查阅批次 COA 获取详细规格。
质量文档
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
文献证明
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
概述
BT44 is a selective RET activator. BT44 can penetrate through the blood-brain barrier and can be used for the research of neurodegenerative disorders and diabetes mellitus.
In Vitro
BT44 (7.5-75 μM; 15 min) promotes RET phosphorylation and selectively activates downstream cascades in the cells expressing GFL receptors. BT44 (0.5-10 μM; 16-20 h) promotes neurite outgrowth from sensory neurons. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: GFRα3-transfected MG87RET cells Concentration: 7.5, 18, 35 and 75 μM Incubation Time: 15 min Result: Increased RET and ERK phosphorylation.
In Vivo
BT44 (5-25 mg/kg; s.c.; every second day for 10, 42 or 14 days) alleviates sensory signs in the SNL and STZ models of neuropathic . BT44 (12.5 or 25 mg/kg; s.c.; every second day for 10 days) protects IB4-positive neurons in DRGs of animals with experimental neuropathy . BT44 (0.1 and 0.3 μg/24 h; infuse into the right dorsal striatum for 14 days) reverses amphetamine-induced motor imbalance and seems to protect dopaminergic fibers in the striatum in 6-OHDA rat model of Parkinson’s disease. BT44 (10 mg/kg; i.v.) penetrates the blood-brain barrier and is rapidly eliminated from the circulation (half-life (t 1/2 ) = 0.72 h) and brain (t 1/2 = 0.47 h) in rats. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Wistar rats, spinal nerve ligation (SNL) and Streptozotocin (STZ; HY-13753)-induced diabetes mellitus models Dosage: 5, 12.5 or 25 mg/kg Administration: Subcutaneous injecton, every second day for 10, 42 or 14 days Result: Alleviated mechanical allodynia in the SNL animals. Treatment with the dose of 5 mg/kg alleviated mechanical hyperalgesia in the STZ-treated animals, while the 12.5 mg/kg dose was not effective. Concentration of 5 mg/kg attenuated cold allodynia in the STZ-treated animals during the first two weeks while the effect of 12.5 mg/kg was not significant. Animal Model: Wistar rats, SNL-induced diabetes mellitus model Dosage: 12.5 or 25 mg/kg Administration: Subcutaneous injecton, every second day for 10 days Result: Led to a significant increase in the number of IB4 expressing neurons in the ipsilateral DRGs. The 12.5 mg/kg dose protected IB4-positive neurons from SNL-induced lesion.
Form:Solid
规格
规格或纯度
≥99%
英文名称
BT44
生化机理
BT44 是一种选择性 RET 激活剂。BT44 可穿透血脑屏障，可用于神经退行性疾病和糖尿病的研究。
储存条件
-20°C储存
运输条件
超低温运输
作用类型
激活剂
纯度
≥99%
名称和识别符
分子类型
小分子
分子量
577.59
技术文档
高级数据
化学和物理性质
溶解性
DMSO : 62.5 mg/mL (108.21 mM; ultrasonic and warming and heat to 60°C)
质检证书（CoA,COO,BSE/TSE 和分析图谱)
C of A & Other Certificates(BSE/TSE, COO):
输入批号以搜索分析图谱:
溶液计算器
产品仅提供给经过验证的企业、机构和合格的专业人员用于研发。不适用于人类、动物、诊断或治疗。
Copyright © 2023至今 上海阿拉丁生化科技股份有限公司 保留所有权利。
危险品化学品经营许可证（带存储）